Cytopia strengthens scientific team
This article was originally published in Scrip
Executive Summary
Cytopia (Australia) has appointed Dr Devron Averett chief scientific advisor. He will work closely with the company's executive management team, on a part-time basis during this year, to provide scientific leadership and guidance. He has held leadership roles at Glaxo Wellcome and Burroughs Wellcome and, in recent years, at Valeant Pharmaceuticals International and Anadys Pharmaceuticals, a company he co-founded. Cytopia is also consolidating its North American operations in Woodside, California, and closing the Rensselaer, New York, office, which is currently led by Dr Shreefal Mehta as vice-president of business and corporate development. Dr Mehta has chosen not to relocate to the west coast and will leave the company at the end of July. Richard Haiduck, who has been working with the company in a strategic consulting role, has been appointed as chief business advisor, with responsibility for Cytopia's global business and corporate development.
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.